Sanofi to Present More Acomplia Data at April 11th Meeting
Sanofi-Aventis, developer of the highly publicized anti–obesity drug Acomplia, will present new data on the drug’s role in reducing metabolic cardiovascular disease risk factors at a scientific meeting in San Diego April 11th and 12th.
Dr. Pierre Rosenzweig, a Vice President of Sanofi-Aventis, will make the presentation at the Annual Metabolic [...]
Support for “Metabolic Syndrome” May Buttress Expanded Role for Acomplia
The American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI) on Sept. 13 issued a new scientific statement taking issue with two major diabetes organizations Acomplia (rimonabant) that a month ago questioned the validity of diagnosing patients with “metabolic syndrome.”
The debate could well impact efforts of [...]
FDA Advisory Panel Says Obese Kids Should Be Included in Drug Trials
A U.S. FDA Advisory Committee reviewing guidelines for weight-loss drug trials appear prepared to call for studies that focus on the effect of anti–obesity drugs on severely obese children Acomplia (rimonabant) .
Acomplia (rimonabant) “This population of patients needs to be studied separately from the [...]
Roche, GlaxoSmithKline Sign Promotional Agreement for Xenical in U.S.
Pharmaceutical giants Roche and GlaxoSmithKline have signed a promotional agreement for weight-loss medication Xenical (orlistat) in the United States, according to a statement issued April 12th.
The pact gives Glaxo exclusive rights to promote prescription Xenical in the United States. Glaxo also acquired the rights to an over-the-counter (OTC) version of the [...]
Will FDA Advisory Committee Consider Acomplia, and When?
The U.S. Food and Drug Administration advisory committee that is expected to weigh in on the new anti–obesity drug Acomplia (rimonabent) prior to an FDA decision on approval apparently does not intend to take up the drug at its December meeting.
The FDA’s Endocrinologic and Metabolic Drugs Advisory [...]
Regulators Will Be Wary in Weighing Up Acomplia
The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti–obesity drug Acomplia, it can expect close scrutiny during the approval process of the side effects.
Want to lose weight, stop smoking and [...]
Dispute Over “Metabolic Syndrome” May Impact Acomplia Approval Process
Two major diabetes organizations in the United States and Europe have taken issue Acomplia (rimonabant) with the efforts of Sanofi-Aventis to get regulators to approve Acomplia (rimonabant) not just as an anti–obesity drug but as a comprehensive approach to treating “metabolic syndrome.”
In fact, the American Diabetes Acomplia [...]
ECRI: Acomplia Could Be Safer for Treating Obesity Than Previous Drugs
ECRI, a nonprofit health services research agency, has published a Health Technology Acomplia (rimonabant) ™ profile on Acomplia, a novel pharmaceutical agent that is in development for the treatment of obesity .
The drug rimonabant (Acomplia) is the first in [...]
